Literature DB >> 11823695

Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.

Steven C Plaxe1, John A Blessing, Mark A Morgan, John Carlson.   

Abstract

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11823695     DOI： 10.1097/00000421-200202000-00009

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN： 0277-3732            Impact factor:   2.339


  5 in total

1.  Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Authors:  Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh
Journal:  Gynecol Oncol       Date:  2011-07-12       Impact factor: 5.482

Review 2.  Management strategies for recurrent platinum-resistant ovarian cancer.

Authors:  R Wendel Naumann; Robert L Coleman
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Authors:  Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2011-03-17       Impact factor: 5.482

4.  Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.

Authors:  Bhuvaneswari Ramaswamy; Ewa Mrozek; John Philip Kuebler; Tanios Bekaii-Saab; Eric H Kraut
Journal:  Invest New Drugs       Date:  2009-10-21       Impact factor: 3.850

5.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Authors:  David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.